IFRX InflaRx N.V. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.84

Period return

+0.78 (+73.58%)

Volume

1.6M

2026-06-05O $1.99 H $1.99 L $1.81 C $1.84MA5 $2.07MA20 $2.39MA60 $1.67MA120 $1.32

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 14.MediumBUY24 days ago
Raymond James: Strong Buy
US analyst rating / recommendation change.
2026. 05. 12.LowBUY26 days ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 05. 11.LowBUY26 days ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $7.36 · 7 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.

Sector: Healthcare
Industry: Biotechnology

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Raymond James	—	Upgrade	Outperform → Strong Buy	—	Raymond James: Outperform → Strong Buy
2026. 05. 12.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 05. 11.	Cantor Fitzgerald	—	Maintain	Overweight → Overweight	—	Cantor Fitzgerald: Overweight
2026. 04. 21.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 03. 20.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2025. 12. 31.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy

InflaRx N.V.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats